Metabolism of 1α,25(OH)2D3 and its 20-epi analog integrates clonal expansion, maturation and apoptosis during HL-60 cell differentiation

Molecular and Cellular Endocrinology

Volumn 149, Issue 1-2, 1999, Pages 169-183

  Campbell, Moray J ^a   Drayson, Mark T ^a   Durham, Jennifer ^a   Wallington, Lisa ^a   Siu Caldera, Mei Ling ^b   Reddy, G Satyanarayana ^b   Brown, Geoffrey ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Apoptosis; Differentiation; Leukemia cells; p21((waf1)); Vitamin D3 metabolites

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; CD14 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; KETOCONAZOLE; LEXACALCITOL; OXYGENASE; PROTEIN P21; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; CYTOCHROME P450; DRUG DERIVATIVE; ENZYME INHIBITOR; STEROID MONOOXYGENASE; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL STRAIN HL 60; CELL TRANSFORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; VITAMIN D METABOLISM; BIOLOGICAL MODEL; CELL DIVISION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

APOPTOSIS; CALCITRIOL; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; KETOCONAZOLE; MODELS, BIOLOGICAL; STEROID HYDROXYLASES;

EID: 0033602290     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(98)00245-7     Document Type: Article

References (67)

1. 3. Proc. Natl Acad. Sci. 78(8):1981;4990-4994.
2. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res. 237:1997;1-6.
3. 3 analogues: a novel class of potent regulators of cell growth and immune response. Biochem. Pharmacol. 42:1991;1569-1575.
4. 3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells. J. Steroid Biochem. Mol. Biol. 59(5/6):1996;405-412.
5. (kip1) and E-cadherin. J. Mol. Endocrinol. 19(1):1997a;15-27.
6. 3 analogs and their 24-oxo metabolites display equally potent inhibition of proliferation against a variety of cancer cell types but do not have the same molecular effects. J. Cell. Biochem. 68(3):1997b;413-425.
7. 3 analog. Endocrinology. 139(4):1998;1972-1980.
8. Carlberg C. Mechanisms of nuclear signalling by vitamin D. Interplay with retinoid and thyroid hormone signalling. Eur. J. Biochem. 231:1995;517-527.
9. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology. 108(3):1981;1083-1086.
10. Cross H.S., Bajna E., Bises G., Genser D., Kallay E., Potzi R., Wenzl E., Roka R., Peterlik M. Vitamin D receptor and cytokeratin expression may be progression indicators in human colon cancer. Anticancer Res. 16(4B):1996;2333-2337.
11. 3 analogue shows relation to promoter selectivity. J. Cell. Biochem. 66(4):1997;552-562.
12. Dilworth F.J., Williams G.R., Kissmeyer A-M., Nielsen J.M., Binderup E., Calverley M.J., Makin H.L., Jones G. The vitamin D analog KH1060 is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology. 138:1997;5485-5496.
13. Dobrovic A, Houle B, Belouchi A, Bradley WEC. The thyroid hormone receptor (THR) maps to the chromosome region 3p21-3p25 and is deleted in small cell lung cancer. Cytogenet. Cell Genet. 46:1987;607-612.
14. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood. 84:1994;1960-1967.
15. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 55(13):1995;2822-2830.
16. Fero M.L., Rivkin M., Tasch M., Porter P., Carow C., Firpo E., Polyak K., Tsai L., Broudy V., Perlmutter R., Kaushansky K., Roberts J.M. A syndrome of multiorgan hyperplasia with features of gigantism, tumourgenisis, and female sterility in p27 deficient mice. Cell. 85:1996;733-744.
17. 3 specifically binds to a human breast cancer cell line (T47D) and stimulates growth. Biochem. Biophys. Res. Commun. 101:1981;1131-1138.
18. Fu G.K., Lin D., Zhang M.Y.H., Bikle D.D., Shackleton C.H.L., Miller W.L., Portale A.A. Cloning of human 25-hydroxyvitamin D-1α-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol. Endocrinol. 11(13):1997;1961-1970.
19. Fuqua S.A.W., Chamness G.C., McGuire W.L. Estrogen receptor mutations in breast cancer. J. Cell. Biochem. 51:1993;135-139.
20. Gaddipati J.P., McLeod D.G., Heidenberg H.B., Sesterhenn I.A., Finger M.J., Moul J.W., Srivastava S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54:1994;2861-2864.
21. Garcia M., Derocq D., Freiss G., Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. Natl. Acad. Sci. 89(23):1992 (Dec. 1);11538-11542.
22. Griffen J.E. Androgen resistance-the clinical and molecular spectrum. New Engl. J. Med. 326:1992;611-618.
23. 3-differentiated HL-60 cells. J. Mol. Endocrinol. 3:1989;199-205.
24. 3 after long term culture. J. Steroid Biochem. Mol. Biol. 38(3):1991;301-306.
25. Hengst L., Reed S. Translational control of p27 accumulation during the cell cycle. Science. 271:1996;1861-1863.
26. Hirama T, Koeffler H.P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 86(3):1995;841-854.
27. Houle B., Rouchette-Egly C., Bradley W.E.C. Tumor-suppressive effect of the retinoic acid receptor-β in human epidermoid lung cancer cells. Proc. Natl. Acad. Sci. 90:1993;985-989.
28. 3 and its analogues on induction of apoptosis in breast cancer cells. J. Steroid Biochem. Mol. Biol. 58(4):1996;395-401.
29. 3 in human skin in vivo. J. Invest. Dermatol. 108:1997;513-518.
30. Kastner P., Perez A., Lutz Y., Rochette-Egly C., Gaub M.P., Durand B., Lanotte M., Berger R., Chambon P. Structure, localization and transcriptional properties of two classes of retinoic acid receptor α fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J. 11:1992;629-642.
31. Kawa S., Nikaido T., Aoki Y., Zhai Y., Kumagai T., Furihata K., Fujii S., Kiyosawa K. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br. J. Cancer. 76(7):1997;884-889.
32. Koeffler H.P., Billing R., Lusis J., Sparkles R., Golde D.W. An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood. 56:1980;265-273.
33. 3: a novel class of potent inhibitors of proliferation of human breast cancer cell lines. Cancer Res. 57:1997;4545-4550.
34. Li X., Daryzynkiewicz Z. Labelling DNA strand breaks with Brd-UTP. Detection of apoptosis and cell proliferation. Cell Prolif. 28:1995;571-579.
35. Liu M., Lee M., Cohen M., Bommakanti M., Freedman L. Transcriptional activation of the Cdk inhibitor p21 by vitamin D leads to the induced differentiation of the myelomonocytic cell line U-937. Genes Dev. 10:1996;142-153.
36. 3 analogues in breast cancer cells. Cancer Res. 56:1996;2789-2794.
37. Maroder M., Vacca A., Screpanti I., Petrangeli E., Frati L., Gulino A. Enhancement of c-erbA proto-oncogene expression by glucocorticoid hormones in S49.1 lymphoma cells. Biochim. Biophys. Acta. 1009(2):1989;188-190.
38. McInerney E.M., Ince B.A., Shapiro D.J., Katzenellenbogen B.S. A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action. Mol. Endocrinol. 10:1996;1519-1526.
39. 3 receptor in bone, lung and other cancers. Mol. Carcinog. 19:1997;254-257.
40. 3. Cancer Res. 52:1992;515-520.
41. 3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res. 1:1995;997-1003.
42. Muller R., Curran T., Muller D., Guilbert L. Induction of c-fos during myelomonocytic differentiation and macrophage proliferation. Nature. 314(11):1985;546-548.
43. Munker R., Norman A., Koeffler H.P. Vitamin D compounds: effect on clonal proliferation and differentiation of human myeloid cells. J. Clin. Invest. 78:1986;424-430.
44. 3 indicates that the 6-s-cis conformation is preferred for rapid non-genoic biological responses and neither 6-s-cis nor 6-s-trans locked analogs are preferred for genomic biological responses. Mol. Endocrinol. 11(10):1997;1518-1531.
45. Omdahl J., May B. The 25-hydroxyvitamin D 24-hydroxylase. Feldman D., Glorieux F.H., Wesley P.J. Vitamin A. 1997;69-85 Academic Press, San Diego, CA.
46. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 275:1997;967-969.
47. Reicharth J., Muller S.M., Kerber A., Baum H.P., Bahmer F.A. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J. Am. Acad. Dermatol. 36(1):1997;19-28.
48. 3 production by cultured porcine alveolar macrophages. Mol.Cell. Endocrinol. 75:1991;163-167.
49. 3 induction in myeloid leukemic cells. Mol. Cell. Biol. 18(4):1998;1911-1918.
50. Sachs L. Control of normal differentiation and the phenotypic reversion of malignancy in myeloid leukemia cells. Nature. 274:1978;535-539.
51. Schwaller J., Koeffler H.P., Nicklaus G., Loetscher P., Nagel S., Fey M.F., Tobler A. Posttranscriptional stabilization underlies p53-independent induction of p21 in differentiating human leukemic cells. J. Clin. Invest. 95:1993;973-979.
52. 3. Cancer Res. 54(15):1994;4057-4064.
53. 3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat. 42(1):1997;31-41.
54. 3 receptors and actions in human prostate cancer cell lines. Endocrinology. 132(5):1993;1952-1960.
55. Small E.J., Baron A.D., Fippin L., Apodaca D. Ketoconazole retains activity an advanced prostate cancer patients with progression despite flutamide withdrawal. J. Urol. 157:1997;1204-1207.
56. Toksoz D., Bunce C.M., Stone P.C.W., Michell R.H., Brown G. Variant cell lines from the human promyelocyte line HL-60. Leuk. Res. 6:1982;491-498.
57. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9:1995;401-406.
58. Torchia J., Glass C., Rosenfeld M.G. Co-activators and co-repressors in the integration of transcriptional responses. Curr. Opin. Cell Biol. 10:1998;373-383.
59. Wallington L.A., Durham J., Bunce C.M., Brown G. Growth of HL-60 cells in liquid culture: analysis of differentiation agents. Leuk. Res. 20:1996;821-829.
60. 3 in HL-60 cells. Cancer Res. 56:1996;264-267.
61. Wang J., Walsh K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science. 273:1996;359-361.
62. 3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced releases of cytochrome c. Exp. Cell Res. 235:1997a;210-217.
63. 3. J. Natl. Cancer Inst. 89(16):1997b;1199-1205.
64. Yam L.T., Li C.Y., Cosby W.W. Cytochemical identification of monocytes and granulocytes. Am. J. Clin. Pathol. 55:1971;283-290.
65. Yang E., Korsmeyer S.J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 88(2):1996;386-401.
66. Yoshizawa T., Handa Y., Uematsu Y., Takeda S., Sekine K., Yoshihara Y., Kawakami T., Arioka K., Sato H., Uchiyama Y., Masushige S., Fukamizu A., Matsumoto T., Kato S. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16:1997;391-396.
67. Zhang W., Grasso L., McClain C.D., Gambel A.M., Cha Y., Travali S., Deisseroth A.N., Mercer W.E. p53-Independent induction of WAF1/CIP1 in human leukaemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res. 55:1995;668-674.